Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions

NCT00180453 is registered in ClinicalTrials.gov with Abbott Medical Devices as lead sponsor.

NCT NCT00180453
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00180453 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SPIRIT First: A Clinical Evaluation of an Investigational Device. The Abbott XIENCE V® Everolimus Eluting Coronary Stent System in the Treatment of Patients With de Novo Native Coronary Artery Lesions
Lead sponsor
Abbott Medical Devices
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
June 30, 2009
Enrollment
60 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

coronary artery disease, coronary artery stenosis, everolimus, myocardial ischemia, vascular disease